Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup
Vistagen reported PALISADE-4 did not meet its primary or secondary endpoints but showed a nominally significant post-hoc benefit in very severe social anxiety disorder patients.Key Highlights:Original SEC Filing: Vistagen Therapeutics, Inc. [ VTGN ] - 8-K - Jun. 30, 2026This is an AI-powered summar…